Ac Immune Sa (ACIU)
$2.38
Insights on Ac Immune Sa
Increasing Revenue
Revenue is up for the last 2 quarters, 1.0K → 14.80M (in $), with an average increase of 100.0% per quarter
Increasing Net Profit
Netprofit is up for the last 5 quarters, -18.74M → -4.74M (in $), with an average increase of 60.4% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 36.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 309.1%
Performance
- $2.36$2.49$2.38
0.76%
Downside
Day's Volatility :5.14%
Upside
4.42%
- $1.78$5.14$2.38
25.21%
Downside
52 Weeks Volatility :65.37%
Upside
53.7%
Returns
| Period | Ac Immune Sa | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -41.69% | -0.7% | 0.0% |
6 Months | -13.26% | 6.6% | 0.0% |
1 Year | 9.75% | 3.7% | -1.5% |
3 Years | -62.83% | 14.0% | -21.8% |
Highlights
Market Capitalization | 242.3M |
Book Value | $1.71 |
Earnings Per Share (EPS) | -0.7 |
PEG Ratio | 0.0 |
Wall Street Target Price | 10.52 |
Profit Margin | 0.0% |
Operating Margin TTM | -23.92% |
Return On Assets TTM | -18.18% |
Return On Equity TTM | -32.9% |
Revenue TTM | 14.8M |
Revenue Per Share TTM | 0.18 |
Quarterly Revenue Growth YOY | 1480000.0% |
Gross Profit TTM | -56.4M |
EBITDA | -52.0M |
Diluted Eps TTM | -0.7 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.75 |
EPS Estimate Next Year | -0.24 |
EPS Estimate Current Quarter | -0.13 |
EPS Estimate Next Quarter | -0.2 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 342.02%
Technicals Summary
Sell
Neutral
Buy
Ac Immune Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Ac Immune Sa | -30.86% | -13.26% | 9.75% | -62.83% | -48.73% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Ac Immune Sa | NA | NA | 0.0 | -0.75 | -0.33 | -0.18 | NA | 1.71 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Ac Immune Sa | Buy | $242.3M | -48.73% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
Bvf Inc
7.52%Avidity Partners Management LP
4.52%BlackRock Inc
2.45%Morgan Stanley - Brokerage Accounts
1.78%Junked Platinum Investment Management Ltd
1.53%Wells Fargo & Co
1.16%
Corporate Announcements
Ac Immune Sa Earnings
Ac Immune Sa’s price-to-earnings ratio stands at None
Read More
Company Information
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Organization | Ac Immune Sa |
Employees | 133 |
CEO | Dr. Andrea Pfeifer Ph.D. |
Industry | Health Technology |
